SONN beat EPS expectations by 10.29%
Aug 21, 2024, 9:36 AM
0.00%
What does SONN do
Sonnet BioTherapeutics Holdings, Inc., headquartered in Princeton, New Jersey, is a clinical-stage biotech company focused on oncology, utilizing its Fully Human Albumin Binding technology to enhance drug delivery in cancer treatment. Key products include SON-1010 for solid tumors and SON-080 for neuropathy conditions, with additional assets in development.
Sonnet BioTherapeutics Holdings (SONN) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Sonnet BioTherapeutics Holdings's actual EPS was -$5.60, beating the estimate of -$6.24 per share, resulting in a 10.29% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.